<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02045446</url>
  </required_header>
  <id_info>
    <org_study_id>STU 092013-070</org_study_id>
    <nct_id>NCT02045446</nct_id>
  </id_info>
  <brief_title>Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial</brief_title>
  <official_title>Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The core hypothesis to be tested is that the use of consolidative SBRT followed by&#xD;
      maintenance chemotherapy in patients with less than or equal to 6 metastatic sites (primary +&#xD;
      5) will improve progression free survival (PFS) compared to maintenance chemotherapy alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol is a randomized phase II trial of maintenance chemotherapy versus consolidative&#xD;
      Stereotactic Body Radiation Therapy (SBRT) plus maintenance chemotherapy for patients with&#xD;
      Stage IV non-small cell lung cancer (NSCLC).&#xD;
&#xD;
      Prior to accrual on the trial, patients with Stage IV NSCLC will be treated with standard&#xD;
      first-line chemotherapy. Patients who achieve a partial response or stable disease by imaging&#xD;
      criteria with fewer than or equal to six sites of oligometastatic disease will be randomized&#xD;
      to maintenance chemotherapy or consolidative SBRT to all sites of disease (followed by&#xD;
      maintenance chemotherapy at the medical oncologist's discretion). Choices of first line and&#xD;
      maintenance chemotherapy will be determined by the medical oncologist based on clinical&#xD;
      appropriateness.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 2014</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluate the effect of SBRT with or without maintenance chemotherapy versus maintenance chemotherapy alone on progression free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Actuarial rate in-field local control</measure>
    <time_frame>5 years</time_frame>
    <description>To describe the actuarial rate in-field local control and rate of out-of-field disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicities</measure>
    <time_frame>2 years</time_frame>
    <description>To evaluate the safety of SBRT with metastatic NSCLC after prior chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>To evaluate overall survival after SBRT followed by maintenance chemotherapy in comparison to maintenance chemotherapy alone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of maintenance chemotherapy</measure>
    <time_frame>5 years</time_frame>
    <description>To evaluate the duration of maintenance chemotherapy and time to initiation of third line systemic agent (chemotherapy or biologic agent)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Stage IV Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Maintenance chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FDA approved drugs for the study population: Bevacizumab, Docetaxel, Erlotinib, Gemcitabine, Pemetrexed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stereotactic Body Radiation Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>consolidative Stereotactic Body Radiation Therapy (SBRT) plus maintenance chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Body Radiation Therapy</intervention_name>
    <arm_group_label>Stereotactic Body Radiation Therapy</arm_group_label>
    <other_name>SBRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maintenance chemotherapy</intervention_name>
    <description>Maintenance chemotherapy</description>
    <arm_group_label>Maintenance chemotherapy</arm_group_label>
    <arm_group_label>Stereotactic Body Radiation Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must have biopsy proven metastatic NSCLC (Stage IV).&#xD;
&#xD;
          2. Patients must have received first line chemotherapy, from 4-6 cycles, and achieved&#xD;
             stable disease or a partial response.&#xD;
&#xD;
          3. Patients receiving first-line erlotinib, gefitinib, or crizotinib for EGFR&#xD;
             mutant-positive or EML4-ALK positive NSCLC will be excluded.&#xD;
&#xD;
          4. Age ≥ 18 years&#xD;
&#xD;
          5. Patients must have measurable disease at baseline.&#xD;
&#xD;
          6. Patients can have up to only 6 discrete active extracranial lesions (≤3 in the liver&#xD;
             and ≤3 in the lung) identified by PET scan and also seen on correlative plain film, CT&#xD;
             scan, or MRI within 8 weeks prior to the initiation of SBRT.&#xD;
&#xD;
               1. For patients who have received prior radiotherapy to the primary site in the&#xD;
                  lung, residual PET activity is difficult to interpret and will not be considered&#xD;
                  a site of active disease if the CT appearance is stable or improved over an&#xD;
                  interval of at least three months&#xD;
&#xD;
               2. Patients who previously received radiotherapy to the primary site will be&#xD;
                  ineligible if there is CT evidence of disease progression within the past 3&#xD;
                  months.&#xD;
&#xD;
               3. Patients with previously un-irradiated primary sites will be potentially&#xD;
                  eligible, but special considerations apply.&#xD;
&#xD;
               4. Up to 2 contiguous vertebral metastases will be considered a single site of&#xD;
                  disease.&#xD;
&#xD;
          7. Patients must have a KPS &gt;60&#xD;
&#xD;
          8. AST, ALT &amp; Alkaline phosphates must be ≤ 2.5X the upper limit of normal. Total&#xD;
             bilirubin must be within the limit of normal.&#xD;
&#xD;
          9. Patients should have adequate bone marrow function as defined by peripheral&#xD;
             granulocyte count of ≥1500/mm³.&#xD;
&#xD;
         10. Patients should have adequate renal function (serum creatinine ≤1.5 times the ULN).&#xD;
&#xD;
         11. Females of childbearing potential should have a negative pregnancy test.&#xD;
&#xD;
         12. Patients who would be receiving SBRT for lung tumors who are known or suspected by the&#xD;
             treating radiation oncologist to have compromised lung function must have a documented&#xD;
             forced expiratory volume in 1 second (FEV1) ≥ 1L.&#xD;
&#xD;
         13. Patients must provide verbal and written informed consent to participate in the study.&#xD;
&#xD;
         14. Total bilirubin: within normal institutional limits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who previously received radiotherapy to the primary site with CT evidence of&#xD;
             disease progression at the primary site within 3 months following the initial&#xD;
             radiotherapy.&#xD;
&#xD;
          2. Patients with either untreated brain metastases or brain metastases treated within the&#xD;
             past three months are ineligible&#xD;
&#xD;
          3. Patients with serious, uncontrolled, concurrent infection(s).&#xD;
&#xD;
          4. Significant weight loss (&gt;10%) in the prior 3 months.&#xD;
&#xD;
          5. Because the tolerance dose of SBRT to the gastrointestinal tract is not established,&#xD;
             patients with metastatic disease invading the esophagus, stomach, intestines, or&#xD;
             mesenteric lymph nodes will not be eligible.&#xD;
&#xD;
          6. Patients with cutaneous metastasis of NSCLC.&#xD;
&#xD;
          7. Treatment for other carcinomas within the last five years, except cured non-melanoma&#xD;
             skin and treated in-situ cancers.&#xD;
&#xD;
          8. Patients with more than 6 discrete extra-cranial lesions.&#xD;
&#xD;
          9. Participation in any investigational drug study within 4 weeks preceding the start of&#xD;
             study treatment.&#xD;
&#xD;
         10. Unwillingness to participate or inability to comply with the protocol for the duration&#xD;
             of the study.&#xD;
&#xD;
         11. Patients who are pregnant. Patients with reproductive capability will need to use&#xD;
             adequate contraception during the time of participation in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Puneeth Iyengar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UTSW</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 14, 2014</study_first_submitted>
  <study_first_submitted_qc>January 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2014</study_first_posted>
  <last_update_submitted>May 13, 2021</last_update_submitted>
  <last_update_submitted_qc>May 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Puneeth Iyengar</investigator_full_name>
    <investigator_title>ASSISTANT PROFESSOR, Radiation Oncology - RO-Radiation Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 10, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT02045446/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 9, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT02045446/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

